Eplerenone Versus PDT: Comparative Study by OCTA

Related Clinical Trial
Eplerenone Versus PDT: Comparative Study by OCTA Pilot Study on Deep Learning in the Eye Panmacular Versus Minimal Micropulse Laser Therapy in Central Serous Chorioretinopathy OCT in Rare Chorioretinal Diseases Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO Selective RPE Laser Treatment (SRT) for Various Macular Diseases Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Eye Patch Therapy for Central Serous Retinopathy (CSR) Multimodal Imaging in Central Serous Chorioretinopathy PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Pseudo-PDT in Central Serous Chorioretinopathy Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC) Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy Effects of OCTA-guided PDT in Acute CSC Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Treatment Trial for Acute Central Serous Chorioretinopathy The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole Selective Retina Therapy With ‘R:GEN’ in Patients With Central Serous Chorioretinopathy 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy Central Serous Chorioretinopathy: Etiology, Course and Prognosis A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Treatment of Chronic Central Serous Chorioretinopathy Via Electromagnetic Stimulation and Platelet- Rich Plasma Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy Eplerenone for the Treatment of Central Serous Chorioretinopathy Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy Optical Coherence Tomography Angiography (OCT-A) and Central Serous Chorioretinopathy (CSC) Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR) Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate Short-Term Oral Mifepristone for Central Serous Chorioretinopathy Methotrexate for Central Serous Chorioretinopathy Treatment Trial Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone for Central Serous Chorioretinopathy High-dose Antioxidants for Central Serous Chorioretinopathy

Brief Title

Eplerenone Versus PDT: Comparative Study by OCTA

Official Title

OCTA in Central Serous Chorioratinopathy Treated With Oral Eplerenone or Hal-fluence Photodynamic Therapy: a Comparative Study

Brief Summary

      The study aims to analyze the changes in OCTA parameters and in choroidal thickness in
      patients affected by central serous chorioretinopathy treated by oral eplerenone and
      half-fluence photodynamic therapy.
    

Detailed Description

      Central serous chorioretinopathy (CSC) is a chorioretinal disease characterized by serous
      detachment due to the dilatation and hyperpermeability of choroidal vessels resulting in the
      accumulation of serous fluid between the neurosensory retina and the retinal pigment
      epithelium.

      Several studies reported the efficacy of half-fluence photodynamic therapy (PDT) and oral
      eplerenone in the CSC treatment inducing a reduction of the choroidal hyperpermeability and
      remodeling the choroidal vascularization.

      This retrospective study aims to perform a quantitative analysis of retinal and CC vessel
      density by OCTA at baseline, 3 and 6 months in patients underwent PDT and patients underwent
      eplerenone.
    


Study Type

Observational


Primary Outcome

Study of vessel density in retinal choriocapillaris networks, using OCTA, in patients underwent half fluence photodynamic therapy and oral eplerenone


Condition

Central Serous Chorioretinopathy

Intervention

Eplerenone

Study Arms / Comparison Groups

 Half fluence photodynamic therapy
Description:  Patients with central serous chorioretinopathy, treated by half-fluence photodynamic therapy

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

30

Start Date

October 1, 2015

Completion Date

November 30, 2017

Primary Completion Date

October 30, 2017

Eligibility Criteria

        Inclusion Criteria:

          -  age older than 30 years

          -  diagnosis of central serous chorioretinopathy

          -  treatment-naïve with half-fluence photodynamic therapy or oral eplerenone

          -  absence of vitreoretinal and vascular retinal diseases

        Exclusion Criteria:

          -  age younger than 30 years

          -  absence of diagnosis of central serous chorioretinopathy

          -  previous treatment with half-fluence photodynamic therapy or oral eplerenone

          -  presence of concomitant vitreoretinal and vascular retinal diseases
      

Gender

All

Ages

30 Years - 60 Years


Contacts

Gilda Cennamo, , 



Administrative Informations


NCT ID

NCT05104138

Organization ID

1010/2021


Responsible Party

Principal Investigator

Study Sponsor

Federico II University


Study Sponsor

Gilda Cennamo, Principal Investigator, Università Federico II


Verification Date

October 2021